OpenEvidence Hits $15 Billion Valuation After $250 Million Round as Doctors Send 42 Million Prompts
Updated
Updated · Ars Technica · Oct 21
OpenEvidence Hits $15 Billion Valuation After $250 Million Round as Doctors Send 42 Million Prompts
1 articles · Updated · Ars Technica · Oct 21
Summary
$250 million in September funding valued OpenEvidence at $15 billion, capping a rapid rise for the Miami-based medical AI startup founded in 2022.
42 million prompts last month from a user base spanning nearly two-thirds of US doctors drove that surge, as physicians used the chatbot to search journals and clinical guidelines for diagnosis and treatment decisions.
$100 million in ad buys had already been booked for 2026 by the end of 2025, and the company is tracking toward $400 million to $500 million in ad revenue by end-2026.
OpenEvidence’s spread has won support from physicians who say it eases workloads, but it is also drawing scrutiny over answer accuracy and the growing role of AI in patient care.
Nearly $1 billion in investment over 18 months has helped it break into a medical software market slow to adopt generative AI, even as OpenAI, Anthropic and incumbents like Wolters Kluwer push into the field.